BTAIQ · BioXcel Therapeutics, Inc.
$0.03
-0.01 (-16.67%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$782,637
Shares
31.31M
Volume · Oct 19
146.57K
Avg daily vol (3M)
5.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.02
Day$0.02–0.03
52W close$0.03–2.33
Avg vol 30d703K
Short int2.0M · 6.3% float · 1.6d
Short vol13%
Last earningsDec 8, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
call held Nov 14, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$742,000
Trailing 12 months
Net income (TTM)
−$70.86M
Trailing 12 months
Revenue growth YoY
+51.7%
Year over year
Operating margin
-6,054.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5,607.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$91.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+286.3%
Year over year · more shares
Price change (1Y)
-98.8%
Trailing year
Short interest
6.3%
Latest settlement · 1.6 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−98%
below
Price vs 50-day avg
−91%
below
RSI (14)
27
oversold
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
−60%
trailing
6-month return
−98%
trailing
YTD return
−98%
this year
Relative strength
−105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 47 funds reported for Sep 30 · net -30.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.28% of float · ▼ -36.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Squeeze score
48
elevated · 0–100
Fundamentals
Revenue growth
−72%
Y/Y
EPS growth
+76%
Y/Y
Free cash flow
$-57.6M
Balance sheet
$81.2M
net debt
Quant / Vol
risk profile
Volatility
163%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
104.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−98%
Bearish
Price vs 50-day avg
−91%
Bearish
RSI (14)
27
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
5 of 47 funds reported for Sep 30 · net -30.0K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.28% of float · ▼ -36.2% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
47 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $2
vs 200-day avg -98%
vs 50-day avg -91%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTAIQ
this stock
BioXcel Therapeutics, Inc.
|
$782,637 | -98.4% | -71.7% | — | 6.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.88B | +1.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.72B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTAIQ | -46.8% | -59.7% | -97.6% | -49.5% | -98.4% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -45.3% | -58.8% | -105.3% | -50.0% | -110.8% |